Claritas: phenotypic and multi-omic readouts to inform rare cancer combination therapy

Ended Definitive Contract Awarded Last action

Contract number
75N91025C00043
Awardee
Awarding agency
Obligated
$300,000

Award facts

Contract value 100% obligated
$300,000.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
Total Small Business
Competition
Full and Open Competition after exclusion of sources · 55 offers Negotiated Proposal / Quote
Pricing
Firm Fixed Price
Place of performance
Durham, NC 27712, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Supplemental Agreement for work within scope P00001 -$54,753
Original award $354,753

About this award

The National Cancer Institute awarded a $300,000 definitive contract to Radiant DX Inc. for CLARITAS—phenotypic and multi-omic readouts to inform rare cancer combination therapy—on August 27, 2025, under a total small business set-aside.

Place of performance is Durham, NC. The contract is firm fixed price with an ultimate completion date of May 26, 2026.

Quick answers

Who was awarded contract 75N91025C00043?

75N91025C00043 was awarded to Radiant DX Inc. by National Cancer Institute (National Institutes of Health) on August 27, 2025.

How much is contract 75N91025C00043 worth?

The government has obligated $300,000 on 75N91025C00043.

Was contract 75N91025C00043 competed?

The extent of competition for 75N91025C00043 was full and open competition after exclusion of sources. The government received 55 offers. It was set aside: Total Small Business.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award